Detalhe da pesquisa
1.
Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis.
J Transl Med;
22(1): 43, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38200582
2.
Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein.
Oncogenesis;
11(1): 67, 2022 Nov 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36333295